In Q4 2025, Cel-Sci generated no revenue and reported a significant net loss driven by ongoing R&D and operating expenses as the company continued advancing Multikine without commercial sales.
No revenue was generated during the quarter as products remain under development.
Net loss in Q4 reflected sustained investment in research and clinical activities.
Operating loss remained substantial due to high R&D and administrative costs.
The company ended the fiscal year with a solid cash balance to fund operations.
Management expects continued losses as it advances clinical development and seeks regulatory approvals, requiring additional capital over time.
Analyze how earnings announcements historically affect stock price performance